Armata Pharmaceuticals
ARMP
25 hedge funds and large institutions have $4.17M invested in Armata Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
9% more funds holding
Funds holding: 23 → 25 (+2)
9% more capital invested
Capital invested by funds: $3.85M → $4.17M (+$329K)
0.02% more ownership
Funds ownership: 3.55% → 3.57% (+0.02%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$128K |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$50.5K |
| 3 |
LFG
Larson Financial Group
St Louis,
Missouri
|
+$2.28K |
| 4 |
TVAMP
Tennessee Valley Asset Management Partners
Knoxville,
Tennessee
|
+$659 |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$623 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$118K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$34.4K |
| 3 |
Renaissance Technologies
New York
|
-$9.21K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$5.31K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5.22K |
ARMP Hedge Fund Activity: Q4 2023 in Review
25 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Armata Pharmaceuticals (ARMP) for Q4 2023, worth a combined $4.17M — up 8.5% from $3.85M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ARMP positions and 1 closed out — a net gain of 2 holders — while 6 added to existing stakes and 5 trimmed.
The largest buyer was Vanguard Group, adding an estimated $128K. The largest seller was Bridgeway Capital Management, cutting an estimated $118K.
- 25 institutional investors held Armata Pharmaceuticals (ARMP) as of Q4 2023, up from 23 in Q3 2023.
- Funds reported $4.17M of Armata Pharmaceuticals stock for Q4 2023, up 8.5% quarter-over-quarter.
- 3 funds opened new Armata Pharmaceuticals positions in Q4 2023 and 1 closed out, a net change of +2 holders.
- The largest Armata Pharmaceuticals buyer in Q4 2023 was Vanguard Group, an estimated $128K added.
- The largest Armata Pharmaceuticals seller in Q4 2023 was Bridgeway Capital Management, an estimated $118K sold.
Based on aggregated 13F filings for Q4 2023.